PT3303334T - Inibidores da tirosina cinase - Google Patents

Inibidores da tirosina cinase

Info

Publication number
PT3303334T
PT3303334T PT167285667T PT16728566T PT3303334T PT 3303334 T PT3303334 T PT 3303334T PT 167285667 T PT167285667 T PT 167285667T PT 16728566 T PT16728566 T PT 16728566T PT 3303334 T PT3303334 T PT 3303334T
Authority
PT
Portugal
Prior art keywords
tyrosine kinase
kinase inhibitors
inhibitors
tyrosine
kinase
Prior art date
Application number
PT167285667T
Other languages
English (en)
Original Assignee
Principia Biopharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Principia Biopharma Inc filed Critical Principia Biopharma Inc
Publication of PT3303334T publication Critical patent/PT3303334T/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/26—Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
    • C07D473/32—Nitrogen atom
    • C07D473/34—Nitrogen atom attached in position 6, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Dermatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Neurology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pulmonology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Transplantation (AREA)
  • Vascular Medicine (AREA)
  • Oncology (AREA)
  • Urology & Nephrology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Diabetes (AREA)
PT167285667T 2015-06-03 2016-06-02 Inibidores da tirosina cinase PT3303334T (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562170547P 2015-06-03 2015-06-03
US201562271689P 2015-12-28 2015-12-28

Publications (1)

Publication Number Publication Date
PT3303334T true PT3303334T (pt) 2021-07-02

Family

ID=56118090

Family Applications (1)

Application Number Title Priority Date Filing Date
PT167285667T PT3303334T (pt) 2015-06-03 2016-06-02 Inibidores da tirosina cinase

Country Status (33)

Country Link
US (5) US20180162861A1 (pt)
EP (3) EP3912979A1 (pt)
JP (2) JP6646072B2 (pt)
KR (3) KR20240070721A (pt)
CN (2) CN113149983B (pt)
AU (2) AU2016270973B2 (pt)
CA (1) CA2987335A1 (pt)
CL (2) CL2017003073A1 (pt)
CO (1) CO2017012947A2 (pt)
CR (1) CR20170593A (pt)
DK (1) DK3303334T3 (pt)
DO (1) DOP2017000279A (pt)
EA (1) EA039006B1 (pt)
ES (1) ES2878030T3 (pt)
HK (1) HK1252378A1 (pt)
HR (1) HRP20211249T1 (pt)
HU (1) HUE055419T2 (pt)
IL (2) IL255946A (pt)
LT (1) LT3303334T (pt)
MX (2) MX395007B (pt)
MY (1) MY190548A (pt)
PE (1) PE20180521A1 (pt)
PH (2) PH12017502203B1 (pt)
PL (1) PL3303334T3 (pt)
PT (1) PT3303334T (pt)
RS (1) RS62290B1 (pt)
SG (1) SG10201912443XA (pt)
SI (1) SI3303334T1 (pt)
TN (1) TN2017000501A1 (pt)
TW (2) TWI810582B (pt)
UA (1) UA124090C2 (pt)
WO (1) WO2016196840A1 (pt)
ZA (2) ZA201708667B (pt)

Families Citing this family (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20150044271A1 (en) 2012-02-27 2015-02-12 O-Ray Pharma, Inc. Solid drug implants for intracochlear delivery of therapeutics for the treatment of otic disorders
SMT201900344T1 (it) 2012-09-10 2019-07-11 Principia Biopharma Inc Composti di pirazolopirimidina come inibitori di chinasi
WO2015080252A1 (ja) 2013-11-29 2015-06-04 株式会社ダイゾー 内容物収容容器、それを用いた内容物収容製品、吐出製品および吐出装置
KR20220027271A (ko) 2014-02-21 2022-03-07 프린시피아 바이오파마, 인코퍼레이티드 Btk 억제제의 염 및 고체 형태
CA2970723C (en) 2014-12-18 2023-09-05 Principia Biopharma Inc. Treatment of pemphigus
KR20240070721A (ko) * 2015-06-03 2024-05-21 프린시피아 바이오파마, 인코퍼레이티드 티로신 키나제 억제제
MA42242A (fr) 2015-06-24 2018-05-02 Principia Biopharma Inc Inhibiteurs de la tyrosine kinase
CN105753863B (zh) * 2015-09-11 2018-07-31 东莞市真兴贝特医药技术有限公司 氧代二氢咪唑并吡啶类化合物及其应用
US10358446B2 (en) * 2015-10-14 2019-07-23 Zibo Biopolar Changsheng Pharmaceutical Co., Ltd. Bruton's tyrosine kinase inhibitors
WO2018005849A1 (en) 2016-06-29 2018-01-04 Principia Biopharma Inc. Modified release formulations of 2-[3-[4-amino-3-(2-fluoro-4-phenoxy-phenyl)pyrazolo[3,4-d]pyrimidin-1-yl]piperidine-1-carbonyl]-4-methyl-4-[4-(oxetan-3-yl)piperazin-1-yl]pent-2-enenitrile
JP6920411B2 (ja) * 2016-07-25 2021-08-18 ネルビアーノ・メデイカル・サイエンシーズ・エツセ・エルレ・エルレ コリンキナーゼ阻害剤としてのプリン及び３−デアザプリンアナログ
US10314844B2 (en) * 2017-02-24 2019-06-11 Gilead Sciences, Inc. Inhibitors of Bruton's tyrosine kinase
EP3789040A4 (en) * 2018-04-27 2022-03-09 ONO Pharmaceutical Co., Ltd. PREVENTIVE AND/OR THERAPEUTIC AGENT FOR AUTOIMMUNE DISEASES WITH A COMPOUND WITH BTK INHIBITING ACTIVITY AS AN INGREDIENT
BR112021000964A2 (pt) 2018-07-25 2021-04-20 Novartis Ag inibidores do inflamassoma de nlrp3
KR102653681B1 (ko) 2018-07-31 2024-04-03 록쏘 온콜로지, 인코포레이티드 (s)-5-아미노-3-(4-((5-플루오로-2-메톡시벤즈아미도)메틸)페닐)-1-(1,1,1-트리플루오로프로판-2-일)-1h-피라졸-4-카르복스아미드의분무-건조된 분산물 및 제제
MY207239A (en) * 2018-09-13 2025-02-08 Kissei Pharmaceutical Imidazopyridinone compound
KR20210142154A (ko) 2019-03-21 2021-11-24 옹쎄오 암 치료를 위한 키나제 억제제와 조합된 dbait 분자
AR119731A1 (es) 2019-05-17 2022-01-05 Novartis Ag Inhibidores del inflamasoma nlrp3
TWI877239B (zh) 2019-10-14 2025-03-21 美商普林斯匹亞生物製藥公司 藉由投予(R)-2-[3-[4-胺基-3-(2-氟-4-苯氧基-苯基)吡唑并[3,4-d]嘧啶-1-基]哌啶-1-羰基]-4-甲基-4-[4-(氧呾-3-基)哌-1-基]戊-2-烯腈來治療免疫血小板減少症之方法
CN114761006A (zh) 2019-11-08 2022-07-15 Inserm(法国国家健康医学研究院) 对激酶抑制剂产生耐药性的癌症的治疗方法
CN113045484B (zh) * 2019-12-27 2024-01-26 南京药石科技股份有限公司 一种2-氨基-2-(1-甲基-4-哌啶基)丙烷-1-醇的制备方法
CN113149891B (zh) * 2020-01-07 2024-02-02 南京药石科技股份有限公司 一种2-氨基-2-（1-甲基-4-哌啶基）乙醇的制备方法
US11969418B2 (en) 2020-01-20 2024-04-30 Genzyme Corporation Therapeutic tyrosine kinase inhibitors for relapsing multiple sclerosis (RMS)
WO2021148581A1 (en) 2020-01-22 2021-07-29 Onxeo Novel dbait molecule and its use
BR112022014149A2 (pt) 2020-01-22 2022-09-27 Principia Biopharma Inc Formas cristalinas de 2-[3-[4-amino-3-(2-fluoro-4-fenóxi-fenil)-1h-pirazolo[3,4-d]pirimidina-1-il]piperidina-1-carbonil]-4-metil-4-[4-(oxetan-3-il)piperazin-1-il]pent-2-enenitrila
CN115397427A (zh) * 2020-03-30 2022-11-25 Igia制药有限公司 酪氨酸激酶抑制剂的儿科制剂
KR20230050363A (ko) * 2020-08-10 2023-04-14 지앙수 헨그루이 파마슈티컬스 컴퍼니 리미티드 질환의 치료에 있어서 btk 저해제의 용도
AU2021325431B2 (en) 2020-08-14 2024-01-18 Novartis Ag Heteroaryl substituted spiropiperidinyl derivatives and pharmaceutical uses thereof
JP2023550591A (ja) 2020-11-02 2023-12-04 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング ＥＧＦＲ阻害薬としての置換１Ｈ－ピラゾロ［４，３－ｃ］及び誘導体
MX2023006854A (es) * 2020-12-10 2023-07-20 Genzyme Corp Forma cristalina de tolebrutinib, metodo de preparacion y uso de la misma.
CN116710452A (zh) * 2020-12-23 2023-09-05 建新公司 4-氨基-3-(4-苯氧基苯基)-1,3-二氢-2h-咪唑并[4,5-c]吡啶-2-酮衍生物及其盐类
EP4267572A1 (en) * 2020-12-23 2023-11-01 Genzyme Corporation 4-amino-3-(4-phenoxyphenyl)-1,3- dihydro-2h-imidazo[4,5-c]pyridin-2-one derivatives and salts thereof
WO2022212893A1 (en) 2021-04-02 2022-10-06 Biogen Ma Inc. Combination treatment methods of multiple sclerosis
WO2022218430A1 (zh) * 2021-04-16 2022-10-20 南京明德新药研发有限公司 咪唑并吡啶类化合物及其应用
WO2022223027A1 (zh) * 2021-04-23 2022-10-27 杭州领业医药科技有限公司 Tolebrutinib晶型、无定型及其制备方法和用途
CN117412749A (zh) * 2021-05-21 2024-01-16 杭州领业医药科技有限公司 Tolebrutinib盐及其晶型、其制备方法、其药物组合物和用途
CN117897381A (zh) 2021-06-11 2024-04-16 建新公司 Tolebrutinib的晶型及其制备方法和用途
WO2023280132A1 (zh) * 2021-07-06 2023-01-12 苏州晶云药物科技股份有限公司 氧代二氢咪唑并吡啶类化合物的晶型及其制备方法
US11793820B2 (en) * 2021-09-24 2023-10-24 Chadwick Donaldson Dry powder foamable formulations for delivery of medicaments through the mucosa
KR20240125005A (ko) 2021-12-21 2024-08-19 프린시피아 바이오파마, 인코퍼레이티드 (r)-1-(1-아크릴로일피페리딘-3-일)-4-아미노-3-(4-페녹시페닐)-1h-이미다조[4,5-c]피리딘-2(3h)-온의결정질 형태 및 이의 염
WO2023172663A1 (en) * 2022-03-09 2023-09-14 Teva Pharmaceuticals International Gmbh Solid state forms of tolebrutinib and of tolebrutinib salts
US20230399313A1 (en) * 2022-06-10 2023-12-14 Advenchen Pharmaceuticals, LLC Biological activities of 5-(2-(4-(4-fluoro-2-methyl-1h-indol-5-yloxy)-6-methoxyquinolin-7-yloxy)ethyl)-5-azaspiro[2.4]-heptan-7-ol crystalline, phosphoric acid salt and its enantiomers
AU2023294689A1 (en) * 2022-06-14 2025-01-30 Principia Biopharma Inc. Methods of making tolebrutinib
CA3259743A1 (en) * 2022-06-22 2023-12-28 Principia Biopharma Inc. METHODS FOR MANUFACTURING MODIFIED BTK INHIBITORS
CN119421712A (zh) 2022-06-30 2025-02-11 普林斯匹亚生物制药公司 用于多发性硬化和重症肌无力的治疗性酪氨酸激酶抑制剂
UY40374A (es) 2022-08-03 2024-02-15 Novartis Ag Inhibidores de inflamasoma nlrp3
KR20250084183A (ko) 2022-10-11 2025-06-10 프린시피아 바이오파마, 인코퍼레이티드 다발성 경화증에 대한 치료용 티로신 키나제 저해제
WO2024099242A1 (zh) * 2022-11-07 2024-05-16 天津征程医药科技有限公司 氘代的氨基吡啶衍生物以及包含该化合物的药物组合物
AU2023408758A1 (en) 2022-12-20 2025-07-31 Principia Biopharma Inc. Drug formulations of (r)-1-(1-acryloylpiperidin-3-yl)-4-amino-3-(4- phenoxyphenyl)-1h-imidazo[4,5-c]pyridin-2(3h)-one
WO2024163542A2 (en) 2023-02-01 2024-08-08 Principia Biopharma Inc. Methods of diagnosing and treating multiple sclerosis
WO2025188862A1 (en) 2024-03-06 2025-09-12 Principia Biopharma Inc. Methods of making tolebrutinib

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2809918A (en) 1955-10-17 1957-10-15 Victor M Hermelin Sustained release pharmaceutical preparations
DE2010416B2 (de) 1970-03-05 1979-03-29 Hoechst Ag, 6000 Frankfurt Oral anwendbare Arzneiform mit Retardwirkung
US3760984A (en) 1971-09-29 1973-09-25 Alza Corp Osmotically powered agent dispensing device with filling means
US4107288A (en) 1974-09-18 1978-08-15 Pharmaceutical Society Of Victoria Injectable compositions, nanoparticles useful therein, and process of manufacturing same
US3952741A (en) 1975-01-09 1976-04-27 Bend Research Inc. Controlled release delivery system by an osmotic bursting mechanism
US4728512A (en) 1985-05-06 1988-03-01 American Home Products Corporation Formulations providing three distinct releases
US4794001A (en) 1986-03-04 1988-12-27 American Home Products Corporation Formulations providing three distinct releases
US5145684A (en) 1991-01-25 1992-09-08 Sterling Drug Inc. Surface modified drug nanoparticles
EP1451173A4 (en) 2001-11-01 2005-10-26 Icagen Inc PIPERIDINE
US20060045822A1 (en) 2004-09-01 2006-03-02 Board Of Regents, The University Of Texas System Plasma polymerization for encapsulating particles
AU2005284835A1 (en) * 2004-09-14 2006-03-23 Novartis Vaccines And Diagnostics Inc. Imidazoquinoline compounds
CA2597587A1 (en) * 2005-02-11 2006-08-17 Coley Pharmaceutical Group, Inc. Oxime and hydroxylamine substituted imidazo[4,5-c] ring compounds and methods
EP2029597A4 (en) 2006-05-31 2011-11-23 Univ California purine analogs
TW200804383A (en) 2006-06-05 2008-01-16 Astrazeneca Ab New compounds
PT2201840E (pt) * 2006-09-22 2012-02-14 Pharmacyclics Inc Inibidores da tirosina quinase de bruton
EP2478361A4 (en) 2009-09-16 2014-05-21 Celgene Avilomics Res Inc CONJUGATES AND INHIBITORS OF PROTEIN KINASE
US7741330B1 (en) * 2009-10-12 2010-06-22 Pharmacyclics, Inc. Pyrazolo-pyrimidine inhibitors of Bruton's tyrosine kinase
MY169745A (en) * 2010-05-31 2019-05-14 Ono Pharmaceutical Co Purinone derivative
PL2710005T3 (pl) * 2011-05-17 2017-07-31 Principia Biopharma Inc. Inhibitory kinazy tyrozynowej
MX2013013331A (es) * 2011-05-17 2014-10-17 Principia Biopharma Inc Derivados de azaindol como inhibidores de tirosina-cinasas.
ES2770550T3 (es) * 2011-05-17 2020-07-02 Univ California Inhibidores de quinasa
NZ626750A (en) * 2011-11-29 2015-08-28 Ono Pharmaceutical Co Purinone derivative hydrochloride
US8501724B1 (en) 2012-01-31 2013-08-06 Pharmacyclics, Inc. Purinone compounds as kinase inhibitors
AU2013277582B2 (en) * 2012-06-18 2017-11-30 Principia Biopharma Inc. Reversible covalent pyrrolo- or pyrazolopyrimidines useful for the treatment cancer and autoimmune diseases
RU2019102203A (ru) 2012-07-11 2019-03-05 Блюпринт Медсинс Корпорейшн Ингибиторы рецептора фактора роста фибробластов
SMT201900344T1 (it) * 2012-09-10 2019-07-11 Principia Biopharma Inc Composti di pirazolopirimidina come inibitori di chinasi
US20140142099A1 (en) * 2012-11-20 2014-05-22 Principia Biopharma Inc. Purinone Derivatives as Tyrosine Kinase Inhibitors
US8957080B2 (en) * 2013-04-09 2015-02-17 Principia Biopharma Inc. Tyrosine kinase inhibitors
KR20240070721A (ko) * 2015-06-03 2024-05-21 프린시피아 바이오파마, 인코퍼레이티드 티로신 키나제 억제제
CN105753863B (zh) 2015-09-11 2018-07-31 东莞市真兴贝特医药技术有限公司 氧代二氢咪唑并吡啶类化合物及其应用
US10358446B2 (en) 2015-10-14 2019-07-23 Zibo Biopolar Changsheng Pharmaceutical Co., Ltd. Bruton's tyrosine kinase inhibitors

Also Published As

Publication number Publication date
MX2021006571A (es) 2022-08-25
CN106459049B (zh) 2020-11-27
CL2017003073A1 (es) 2018-06-08
HK1252378A1 (zh) 2019-05-24
IL279258B (en) 2022-04-01
AU2016270973A1 (en) 2018-01-18
CN113149983B (zh) 2024-03-29
TWI732765B (zh) 2021-07-11
DK3303334T3 (da) 2021-06-28
PE20180521A1 (es) 2018-03-14
LT3303334T (lt) 2021-07-12
MX2017015470A (es) 2018-08-15
US9688676B2 (en) 2017-06-27
SI3303334T1 (sl) 2021-09-30
AU2020203447A1 (en) 2020-06-11
US20210171526A1 (en) 2021-06-10
ZA201708667B (en) 2024-07-31
TWI810582B (zh) 2023-08-01
NZ776815A (en) 2024-10-25
EP3303334A1 (en) 2018-04-11
JP6646072B2 (ja) 2020-02-14
DOP2017000279A (es) 2018-04-15
MX395007B (es) 2025-03-24
TW201713654A (zh) 2017-04-16
EP3912979A1 (en) 2021-11-24
AU2016270973B2 (en) 2020-05-14
MX383213B (es) 2025-03-13
EP4112618A1 (en) 2023-01-04
JP6985433B2 (ja) 2021-12-22
CN106459049A (zh) 2017-02-22
UA124090C2 (uk) 2021-07-21
JP2020073561A (ja) 2020-05-14
SG10201912443XA (en) 2020-02-27
AU2020203447B2 (en) 2021-04-01
PH12017502203A1 (en) 2018-06-11
KR102666352B1 (ko) 2024-05-17
CA2987335A1 (en) 2016-12-08
HRP20211249T1 (hr) 2021-11-12
NZ738458A (en) 2024-10-25
RS62290B1 (sr) 2021-09-30
CL2019002150A1 (es) 2019-11-29
KR20220146657A (ko) 2022-11-01
EA201792529A1 (ru) 2018-05-31
PL3303334T3 (pl) 2021-11-08
ES2878030T3 (es) 2021-11-18
KR102552653B1 (ko) 2023-07-07
KR20240070721A (ko) 2024-05-21
WO2016196840A1 (en) 2016-12-08
IL255946A (en) 2018-01-31
ZA202401324B (en) 2025-05-28
US20250197402A1 (en) 2025-06-19
US20180162861A1 (en) 2018-06-14
CR20170593A (es) 2018-05-14
US20170129890A1 (en) 2017-05-11
US20230151012A1 (en) 2023-05-18
CN113149983A (zh) 2021-07-23
EP3303334B1 (en) 2021-06-02
JP2018516935A (ja) 2018-06-28
PH12017502203B1 (en) 2022-07-22
TN2017000501A1 (en) 2019-04-12
TW202210478A (zh) 2022-03-16
IL279258A (en) 2021-01-31
KR20180021730A (ko) 2018-03-05
HUE055419T2 (hu) 2021-11-29
EA039006B1 (ru) 2021-11-19
CO2017012947A2 (es) 2018-03-28
PH12021551681A1 (en) 2023-08-23
BR112017025850A2 (pt) 2018-08-14
MY190548A (en) 2022-04-27

Similar Documents

Publication Publication Date Title
IL279258B (en) tyrosine kinase inhibitors
HUS2400003I1 (hu) Kináz inhibitorként alkalmas vegyületek
IL268614B (en) Aminotriazolopyridines as kinase inhibitors
MA42242A (fr) Inhibiteurs de la tyrosine kinase
ZA201606767B (en) Biaryl kinase inhibitors
EP3347018A4 (en) HEMMER OF CYCLINE-DEPENDENT KINASES
PL3305788T3 (pl) Inhibitor kinazy janusowej
IL274207A (en) Aminoimidazopyridazines as kinase inhibitors
ZA201808238B (en) Certain protein kinase inhibitors
GB201519381D0 (en) Kinase inhibitors
GB201519382D0 (en) Kinase inhibitors
GB201614783D0 (en) Kinases inhibitors
AU2015904223A0 (en) Novel kinase inhibitors i
GB201522245D0 (en) Compounds useful as kinase inhibitors
GB201509381D0 (en) Novel compounds and their use as kinase inhibitors
AU2015903106A0 (en) Novel kinase inhibitors ii
GB201505460D0 (en) Novel compounds and their use as kinase inhibitors